Hester Biosciences Limited

As of June 30, 2026, Hester Biosciences Limited carries a market capitalization of 18.29B, placing it among publicly traded companies globally. Its enterprise value stands at 18.29B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Hester Biosciences Limited's next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2026, Hester Biosciences Limited has 8.51M shares outstanding.

As of June 30, 2026, Hester Biosciences Limited trades at a trailing price-to-earnings ratio of 13.16.

As of June 30, 2026, Hester Biosciences Limited trades at an EV/EBITDA multiple of 20.42 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 5.62 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 26.97 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 18.29B versus a market cap of 18.29B, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 4.89M in revenue per employee across its workforce of 666.50, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Hester Biosciences Limited recorded 204.11M in income tax expense. That works out to an effective tax rate of 28.36, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 719.81M, leaving 1.36B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Hester Biosciences Limited's stock has gained approximately 19.57% over the past 52 weeks. The 50-day moving average sits at 2,245.93, while the 200-day moving average is 1,899.32.

Over the twelve months ended June 30, 2026, Hester Biosciences Limited generated 3.26B in revenue and converted that into 1.36B in net income, yielding earnings per share of 61.89. EBITDA reached 895.56M, while operating income came in at 648.77M.

Over the twelve months ended June 30, 2026, Hester Biosciences Limited posted a gross margin of 76.49, reflecting its pricing power and cost economics. The operating margin of 19.92 and net profit margin of 41.81 provide insight into operational efficiency.

Hester Biosciences Limited's most recent stock split took place on September 27, 2012 with a 2:3 split ratio.